AA
ENTA icon

ALPS Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

ALPS Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,257
Closed -$89.7K – 1037
2025
Q1 		$89.7K Sell
16,257
-880
-5% -$5.44K ﹤0.01% 981
2024
Q4 		$98.5K Buy
17,137
+1,099
+7% +$10.5K ﹤0.01% 986
2024
Q3 		$166K Sell
16,038
-484
-3% -$6.33K ﹤0.01% 983
2024
Q2 		$214K Buy
16,522
+1,602
+11% +$21.6K ﹤0.01% 949
2024
Q1 		$261K Buy
14,920
+319
+2% +$4.22K ﹤0.01% 939
2023
Q4 		$137K Sell
14,601
-896
-6% -$8.35K ﹤0.01% 950
2023
Q3 		$173K Buy
15,497
+21
+0.1% +$338 ﹤0.01% 963
2023
Q2 		$331K Buy
15,476
+1,717
+12% +$50.6K ﹤0.01% 785
2023
Q1 		$556K Sell
13,759
-320
-2% -$15.3K ﹤0.01% 578
2022
Q4 		$655K Buy
14,079
+2,794
+25% +$127K 0.01% 542
2022
Q3 		$585K Sell
11,285
-1,002
-8% -$58.5K 0.01% 566
2022
Q2 		$581K Sell
12,287
-8,816
-42% -$478K 0.01% 557
2022
Q1 		$1.5M Sell
21,103
-2,418
-10% -$157K 0.02% 273
2021
Q4 		$1.76M Sell
23,521
-1,250
-5% -$98.1K 0.02% 302
2021
Q3 		$1.41M Sell
24,771
-1,826
-7% -$90.3K 0.01% 357
2021
Q2 		$1.17M Sell
26,597
-9,727
-27% -$476K 0.01% 386
2021
Q1 		$1.79M Buy
36,324
+32
+0.1% +$1.6K 0.02% 330
2020
Q4 		$1.53M Buy
36,292
+10,697
+42% +$471K 0.02% 343
2020
Q3 		$1.17M Sell
25,595
-1,690
-6% -$81.9K 0.02% 330
2020
Q2 		$1.37M Sell
27,285
-8,581
-24% -$444K 0.02% 268
2020
Q1 		$1.84M Sell
35,866
-3,878
-10% -$207K 0.03% 221
2019
Q4 		$2.46M Buy
39,744
+470
+1% +$29.1K 0.02% 210
2019
Q3 		$2.36M Sell
39,274
-5,412
-12% -$402K 0.02% 199
2019
Q2 		$3.77M Sell
44,686
-6,184
-12% -$556K 0.03% 171
2019
Q1 		$4.86M Buy
50,870
+1,030
+2% +$92.4K 0.03% 167
2018
Q4 		$3.53M Buy
49,840
+10,156
+26% +$779K 0.03% 181
2018
Q3 		$3.39M Buy
39,684
+6,549
+20% +$656K 0.02% 193
2018
Q2 		$3.84M Buy
33,135
+1,872
+6% +$187K 0.03% 191
2018
Q1 		$2.53M Buy
31,263
+10,169
+48% +$783K 0.02% 190
2017
Q4 		$1.24M Buy
21,094
+2,347
+13% +$118K 0.01% 226
2017
Q3 		$877K Buy
18,747
+1,565
+9% +$62.9K 0.01% 265
2017
Q2 		$618K Buy
17,182
+806
+5% +$25.8K ﹤0.01% 340
2017
Q1 		$504K Sell
16,376
-19,951
-55% -$621K ﹤0.01% 407
2016
Q4 		$1.22M Sell
36,327
-5,803
-14% -$166K 0.01% 204
2016
Q3 		$1.12M Buy
42,130
+857
+2% +$19.9K 0.01% 217
2016
Q2 		$910K Buy
41,273
+4,273
+12% +$112K 0.01% 209
2016
Q1 		$1.09M Buy
37,000
+466
+1% +$13K 0.01% 186
2015
Q4 		$1.21M Sell
36,534
-4,640
-11% -$151K 0.01% 210
2015
Q3 		$14.9K Buy
41,174
+7,326
+22% +$315K 0.02% 186
2015
Q2 		$1.52M Buy
33,848
+9,469
+39% +$368K 0.01% 183
2015
Q1 		$746K Buy
24,379
+10,805
+80% +$420K 0.01% 200
2014
Q4 		$690K Sell
13,574
-1,326
-9% -$59.4K 0.01% 192
2014
Q3 		$590K Buy
+14,900
New +$594K ﹤0.01% 321

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's ENTA Position: Q2 2025 in Review

ALPS Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2025, closing a stake of 16,257 shares — an estimated $89.7K sold.

ALPS Advisors first reported a position in ENTA in Q3 2014 and held it in 43 quarters. The position peaked at $4.86M in Q1 2019. 107 funds tracked by Wall St. Rank hold ENTA as of Q2 2025.

  • ALPS Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 16,257 Enanta Pharmaceuticals shares in Q2 2025, an estimated $89.7K.
  • ALPS Advisors first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 43 quarters.
  • ALPS Advisors's Enanta Pharmaceuticals position peaked at $4.86M in Q1 2019.
  • 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.